View ValuationPro Medicus 将来の成長Future 基準チェック /36Pro Medicus利益と収益がそれぞれ年間5.7%と17.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に41.8% 5.6%なると予測されています。主要情報5.7%収益成長率5.64%EPS成長率Healthcare Services 収益成長20.5%収益成長率17.2%将来の株主資本利益率41.80%アナリストカバレッジGood最終更新日19 Aug 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • 4hFull year 2026 earnings released: EPS: AU$2.54 (vs AU$1.10 in FY 2025)Full year 2026 results: EPS: AU$2.54 (up from AU$1.10 in FY 2025). Revenue: AU$261.7m (up 23% from FY 2025). Net income: AU$265.3m (up 130% from FY 2025). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 18Pro Medicus Limited Announces Ordinary Fully Paid Dividend for the Twelve Months Ended June 30, 2026, Payable on September 29, 2026Pro Medicus Limited announced Ordinary Fully Paid Dividend of AUD 0.37000000 per security for the Twelve Months Ended June 30, 2026. record date: September 8, 2026, Ex-date: September 7, 2026, payable on September 29, 2026.Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €96.22, the stock trades at a forward P/E ratio of 82x. Average forward P/E is 13x in the Healthcare Services industry in Europe. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €42.53 per share.お知らせ • Jul 16Pro Medicus Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Pro Medicus Limited announced that they will report fiscal year 2026 results on Aug 18, 2026お知らせ • Jul 08Pro Medicus Limited Announces Appointment of Garry Sherriff to Head of Investor Relations, Effective July 20, 2026Pro Medicus Limited announced the appointment of Garry Sherriff to the role of Head of Investor Relations, effective July 20, 2026. Garry is a senior financial markets executive with over 20 years’ experience spanning equity research, investment banking, corporate finance, strategy, operations and management. During this time, he has developed deep institutional investor relationships across the Australian and overseas markets. In his previous roles as Head of Australian Equities Research & Lead Technology Analyst for the Royal Bank of Canada, and as Head of Australian Emerging Companies Equity Research for Moelis & Company (now MA Financial), Garry established a proven track record covering Pro Medicus and the broader ASX technology sector.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 34%After last week's 34% share price gain to €101, the stock trades at a forward P/E ratio of 78x. Average forward P/E is 15x in the Healthcare Services industry in Europe. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.81 per share.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 12Pro Medicus Limited Announces Interim Dividend for the six months ended December 31, 2025, Payable on March 20, 2026Pro Medicus Limited announced Interim dividend for the six months ended December 31, 2025 . The distribution will be paid on PME – Ordinary Fully Paid securities. This is a new announcement dated 12 February 2026. The distribution amount is AUD 0.32000000 per security. The ex-date is 26 February 2026, the record date is 27 February 2026, and the payment date is 20 March 2026.お知らせ • Jan 19Pro Medicus Limited to Report First Half, 2026 Results on Feb 12, 2026Pro Medicus Limited announced that they will report first half, 2026 results on Feb 12, 2026お知らせ • Sep 24Pro Medicus Limited, Annual General Meeting, Nov 24, 2025Pro Medicus Limited, Annual General Meeting, Nov 24, 2025. Location: leonda by the yarra, 2 wallen road, hawthorn, vic 3122, Australiaお知らせ • Jul 07Pro Medicus Limited to Report Fiscal Year 2025 Results on Aug 14, 2025Pro Medicus Limited announced that they will report fiscal year 2025 results on Aug 14, 2025お知らせ • Feb 13Pro Medicus Limited Declares Interim Franked Dividend for the Six Months Ended December 31, 2024, Payable on March 21, 2025The Board of Pro Medicus Limited is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. Consistent with the Company's dividend policy, the company declared fully franked interim dividend for the six months ended December 31, 2024 is AUD 0.25000000 per share amounting to AUD 26,125,000, payable on 21 March 2025 against AUD 0.18000000 per share in 2024. Record date is on February 28, 2025. Ex-date is on February 27, 2025.お知らせ • Jan 21Pro Medicus Limited to Report First Half, 2025 Results on Feb 12, 2025Pro Medicus Limited announced that they will report first half, 2025 results on Feb 12, 2025Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 08Pro Medicus Limited, Annual General Meeting, Nov 25, 2024Pro Medicus Limited, Annual General Meeting, Nov 25, 2024. Location: at leonda by the yarra, 2 wallen road, hawthorn, vic 3122., AustraliaDeclared Dividend • Aug 16Final dividend of AU$0.22 announcedShareholders will receive a dividend of AU$0.22. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 50%. Cash payout ratio: 61%.New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Reported Earnings • Aug 14Full year 2024 earnings released: EPS: AU$0.79 (vs AU$0.58 in FY 2023)Full year 2024 results: EPS: AU$0.79 (up from AU$0.58 in FY 2023). Revenue: AU$166.3m (up 33% from FY 2023). Net income: AU$82.8m (up 37% from FY 2023). Profit margin: 50% (up from 49% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 12Pro Medicus Limited to Report Fiscal Year 2024 Results on Aug 14, 2024Pro Medicus Limited announced that they will report fiscal year 2024 results on Aug 14, 2024Upcoming Dividend • Feb 22Upcoming dividend of AU$0.18 per shareEligible shareholders must have bought the stock before 29 February 2024. Payment date: 22 March 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.3%). Lower than average of industry peers (1.4%).Declared Dividend • Feb 18First half dividend of AU$0.18 announcedShareholders will receive a dividend of AU$0.18. Ex-date: 29th February 2024 Payment date: 22nd March 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 52%. Cash payout ratio: 58%.Reported Earnings • Feb 16First half 2024 earnings released: EPS: AU$0.35 (vs AU$0.26 in 1H 2023)First half 2024 results: EPS: AU$0.35 (up from AU$0.26 in 1H 2023). Revenue: AU$74.1m (up 30% from 1H 2023). Net income: AU$36.3m (up 33% from 1H 2023). Profit margin: 49% (up from 48% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 16Pro Medicus Limited to Report First Half, 2024 Results on Feb 15, 2024Pro Medicus Limited announced that they will report first half, 2024 results on Feb 15, 2024Recent Insider Transactions • Nov 30Co-Founder recently sold €53m worth of stockOn the 21st of November, Anthony Hall sold around 1m shares on-market at roughly €52.86 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anthony has been a net seller over the last 12 months, reducing personal holdings by €92m.New Risk • Nov 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €53m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Significant insider selling over the past 3 months (€53m sold).お知らせ • Oct 10Pro Medicus Limited, Annual General Meeting, Nov 20, 2023Pro Medicus Limited, Annual General Meeting, Nov 20, 2023, at 10:00 AUS Eastern Standard Time. Location: The Yarra, 2 Wallen Road Leonda Hawthorn AustraliaBoard Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Aug 30Upcoming dividend of AU$0.17 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 September 2023. Payment date: 28 September 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.3%).New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$0.58 (vs AU$0.43 in FY 2022)Full year 2023 results: EPS: AU$0.58 (up from AU$0.43 in FY 2022). Revenue: AU$127.3m (up 35% from FY 2022). Net income: AU$60.6m (up 37% from FY 2022). Profit margin: 48% (in line with FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 22Pro Medicus Limited to Report Fiscal Year 2023 Final Results on Aug 15, 2023Pro Medicus Limited announced that they will report fiscal year 2023 final results on Aug 15, 2023Recent Insider Transactions • Mar 15Chairman recently sold €1.9m worth of stockOn the 13th of March, Peter Kempen sold around 50k shares on-market at roughly €38.19 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.Upcoming Dividend • Feb 23Upcoming dividend of AU$0.13 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 March 2023. Payment date: 24 March 2023. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.3%).Reported Earnings • Feb 16First half 2023 earnings released: EPS: AU$0.26 (vs AU$0.20 in 1H 2022)First half 2023 results: EPS: AU$0.26 (up from AU$0.20 in 1H 2022). Revenue: AU$56.9m (up 28% from 1H 2022). Net income: AU$27.2m (up 32% from 1H 2022). Profit margin: 48% (up from 47% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 15Pro Medicus Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 24, 2023Pro Medicus Limited announced dividend for the six months ended December 31, 2022 of AUD 0.13000000 per share. Ex-date is March 2, 2023. Record date is March 3, 2023. Payment date is March 24, 2023.お知らせ • Jan 24Pro Medicus Limited to Report First Half, 2023 Results on Feb 15, 2023Pro Medicus Limited announced that they will report first half, 2023 results on Feb 15, 2023Upcoming Dividend • Sep 01Upcoming dividend of AU$0.12 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.4%).Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.43 (vs AU$0.30 in FY 2021)Full year 2022 results: EPS: AU$0.43 (up from AU$0.30 in FY 2021). Revenue: AU$94.1m (up 38% from FY 2021). Net income: AU$44.4m (up 44% from FY 2021). Profit margin: 47% (up from 45% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 24%, compared to a 16% growth forecast for the Healthcare Services industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.Upcoming Dividend • Feb 24Upcoming dividend of AU$0.10 per shareEligible shareholders must have bought the stock before 03 March 2022. Payment date: 25 March 2022. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (1.2%).Reported Earnings • Feb 17First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$0.20 (up from AU$0.13 in 1H 2021). Revenue: AU$44.3m (up 40% from 1H 2021). Net income: AU$20.7m (up 53% from 1H 2021). Profit margin: 47% (up from 43% in 1H 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 28%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 02Upcoming dividend of AU$0.08 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 01 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.9%).Reported Earnings • Aug 18Full year 2021 earnings released: EPS AU$0.30 (vs AU$0.22 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$68.1m (up 20% from FY 2020). Net income: AU$30.9m (up 34% from FY 2020). Profit margin: 45% (up from 41% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Mar 03New 90-day high: €30.54The company is up 69% from its price of €18.12 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.97 per share.Upcoming Dividend • Feb 25Upcoming Dividend of AU$0.07 Per ShareWill be paid on the 19th of March to those who are registered shareholders by the 4th of March. The trailing yield of 0.3% is below the top quartile of German dividend payers (3.4%), and is lower than industry peers (1.0%).Recent Insider Transactions • Feb 23Co-Founder recently sold €30m worth of stockOn the 18th of February, Anthony Hall sold around 1m shares on-market at roughly €29.50 per share. This was the largest sale by an insider in the last 3 months. Anthony has been a seller over the last 12 months, reducing personal holdings by €29m.Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 37%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.Reported Earnings • Feb 18First half 2021 earnings released: EPS AU$0.13 (vs AU$0.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$31.6m (up 7.8% from 1H 2020). Net income: AU$13.5m (up 12% from 1H 2020). Profit margin: 43% (up from 41% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 08New 90-day high: €27.85The company is up 40% from its price of €19.94 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.53 per share.Is New 90 Day High Low • Jan 14New 90-day high: €23.11The company is up 29% from its price of €17.91 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.71 per share.Is New 90 Day High Low • Dec 19New 90-day high: €20.91The company is up 37% from its price of €15.25 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.36 per share.Is New 90 Day High Low • Nov 05New 90-day high: €20.58The company is up 45% from its price of €14.15 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.26 per share.Is New 90 Day High Low • Oct 08New 90-day high: €17.07The company is up 11% from its price of €15.40 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.05 per share.業績と収益の成長予測DB:PMC - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2029507286263274126/30/2028421238216229146/30/2027338186179191146/30/2026262265119127N/A3/31/2026251250119128N/A12/31/2025241235120128N/A9/30/2025227175112120N/A6/30/2025213115104111N/A3/31/202519910799107N/A12/31/20241859895102N/A9/30/2024173918592N/A6/30/2024162837582N/A3/31/2024152767077N/A12/31/2023142706571N/A9/30/2023134656067N/A6/30/2023125615663N/A3/31/2023115565159N/A12/31/2022106514755N/A9/30/2022100485058N/A6/30/202293445362N/A3/31/202287414755N/A12/31/202181384149N/A9/30/202174343644N/A6/30/202168313139N/A3/31/202164282736N/A12/31/202059252432N/A9/30/202058242432N/A6/30/202057232431N/A3/31/20205523N/A33N/A12/31/20195422N/A34N/A9/30/20195221N/A30N/A6/30/20195019N/A25N/A3/31/20194717N/AN/AN/A12/31/20184316N/A14N/A9/30/20183913N/A14N/A6/30/20183410N/A14N/A3/31/2018339N/AN/AN/A12/31/2017328N/A15N/A9/30/2017329N/A15N/A6/30/2017329N/A15N/A3/31/2017309N/A13N/A12/31/2016288N/A12N/A9/30/2016287N/A11N/A6/30/2016286N/A11N/A3/31/2016255N/A9N/A12/31/2015235N/A8N/A9/30/2015204N/A6N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PMCの予測収益成長率 (年間5.7% ) は 貯蓄率 ( 2.1% ) を上回っています。収益対市場: PMCの収益 ( 5.7% ) German市場 ( 15.3% ) よりも低い成長が予測されています。高成長収益: PMCの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: PMCの収益 ( 17.2% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: PMCの収益 ( 17.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PMCの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 41.8 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/19 02:34終値2026/08/19 00:00収益2026/06/30年間収益2026/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pro Medicus Limited 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Josh KannourakisBarrenjoey Markets Pty LimitedJohn HesterBell PotterMadeleine WilliamsCanaccord Genuity20 その他のアナリストを表示
Reported Earnings • 4hFull year 2026 earnings released: EPS: AU$2.54 (vs AU$1.10 in FY 2025)Full year 2026 results: EPS: AU$2.54 (up from AU$1.10 in FY 2025). Revenue: AU$261.7m (up 23% from FY 2025). Net income: AU$265.3m (up 130% from FY 2025). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 18Pro Medicus Limited Announces Ordinary Fully Paid Dividend for the Twelve Months Ended June 30, 2026, Payable on September 29, 2026Pro Medicus Limited announced Ordinary Fully Paid Dividend of AUD 0.37000000 per security for the Twelve Months Ended June 30, 2026. record date: September 8, 2026, Ex-date: September 7, 2026, payable on September 29, 2026.
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €96.22, the stock trades at a forward P/E ratio of 82x. Average forward P/E is 13x in the Healthcare Services industry in Europe. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €42.53 per share.
お知らせ • Jul 16Pro Medicus Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Pro Medicus Limited announced that they will report fiscal year 2026 results on Aug 18, 2026
お知らせ • Jul 08Pro Medicus Limited Announces Appointment of Garry Sherriff to Head of Investor Relations, Effective July 20, 2026Pro Medicus Limited announced the appointment of Garry Sherriff to the role of Head of Investor Relations, effective July 20, 2026. Garry is a senior financial markets executive with over 20 years’ experience spanning equity research, investment banking, corporate finance, strategy, operations and management. During this time, he has developed deep institutional investor relationships across the Australian and overseas markets. In his previous roles as Head of Australian Equities Research & Lead Technology Analyst for the Royal Bank of Canada, and as Head of Australian Emerging Companies Equity Research for Moelis & Company (now MA Financial), Garry established a proven track record covering Pro Medicus and the broader ASX technology sector.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 34%After last week's 34% share price gain to €101, the stock trades at a forward P/E ratio of 78x. Average forward P/E is 15x in the Healthcare Services industry in Europe. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.81 per share.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 12Pro Medicus Limited Announces Interim Dividend for the six months ended December 31, 2025, Payable on March 20, 2026Pro Medicus Limited announced Interim dividend for the six months ended December 31, 2025 . The distribution will be paid on PME – Ordinary Fully Paid securities. This is a new announcement dated 12 February 2026. The distribution amount is AUD 0.32000000 per security. The ex-date is 26 February 2026, the record date is 27 February 2026, and the payment date is 20 March 2026.
お知らせ • Jan 19Pro Medicus Limited to Report First Half, 2026 Results on Feb 12, 2026Pro Medicus Limited announced that they will report first half, 2026 results on Feb 12, 2026
お知らせ • Sep 24Pro Medicus Limited, Annual General Meeting, Nov 24, 2025Pro Medicus Limited, Annual General Meeting, Nov 24, 2025. Location: leonda by the yarra, 2 wallen road, hawthorn, vic 3122, Australia
お知らせ • Jul 07Pro Medicus Limited to Report Fiscal Year 2025 Results on Aug 14, 2025Pro Medicus Limited announced that they will report fiscal year 2025 results on Aug 14, 2025
お知らせ • Feb 13Pro Medicus Limited Declares Interim Franked Dividend for the Six Months Ended December 31, 2024, Payable on March 21, 2025The Board of Pro Medicus Limited is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. Consistent with the Company's dividend policy, the company declared fully franked interim dividend for the six months ended December 31, 2024 is AUD 0.25000000 per share amounting to AUD 26,125,000, payable on 21 March 2025 against AUD 0.18000000 per share in 2024. Record date is on February 28, 2025. Ex-date is on February 27, 2025.
お知らせ • Jan 21Pro Medicus Limited to Report First Half, 2025 Results on Feb 12, 2025Pro Medicus Limited announced that they will report first half, 2025 results on Feb 12, 2025
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 08Pro Medicus Limited, Annual General Meeting, Nov 25, 2024Pro Medicus Limited, Annual General Meeting, Nov 25, 2024. Location: at leonda by the yarra, 2 wallen road, hawthorn, vic 3122., Australia
Declared Dividend • Aug 16Final dividend of AU$0.22 announcedShareholders will receive a dividend of AU$0.22. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 50%. Cash payout ratio: 61%.
New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Reported Earnings • Aug 14Full year 2024 earnings released: EPS: AU$0.79 (vs AU$0.58 in FY 2023)Full year 2024 results: EPS: AU$0.79 (up from AU$0.58 in FY 2023). Revenue: AU$166.3m (up 33% from FY 2023). Net income: AU$82.8m (up 37% from FY 2023). Profit margin: 50% (up from 49% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 12Pro Medicus Limited to Report Fiscal Year 2024 Results on Aug 14, 2024Pro Medicus Limited announced that they will report fiscal year 2024 results on Aug 14, 2024
Upcoming Dividend • Feb 22Upcoming dividend of AU$0.18 per shareEligible shareholders must have bought the stock before 29 February 2024. Payment date: 22 March 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.3%). Lower than average of industry peers (1.4%).
Declared Dividend • Feb 18First half dividend of AU$0.18 announcedShareholders will receive a dividend of AU$0.18. Ex-date: 29th February 2024 Payment date: 22nd March 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 52%. Cash payout ratio: 58%.
Reported Earnings • Feb 16First half 2024 earnings released: EPS: AU$0.35 (vs AU$0.26 in 1H 2023)First half 2024 results: EPS: AU$0.35 (up from AU$0.26 in 1H 2023). Revenue: AU$74.1m (up 30% from 1H 2023). Net income: AU$36.3m (up 33% from 1H 2023). Profit margin: 49% (up from 48% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 16Pro Medicus Limited to Report First Half, 2024 Results on Feb 15, 2024Pro Medicus Limited announced that they will report first half, 2024 results on Feb 15, 2024
Recent Insider Transactions • Nov 30Co-Founder recently sold €53m worth of stockOn the 21st of November, Anthony Hall sold around 1m shares on-market at roughly €52.86 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anthony has been a net seller over the last 12 months, reducing personal holdings by €92m.
New Risk • Nov 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €53m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Significant insider selling over the past 3 months (€53m sold).
お知らせ • Oct 10Pro Medicus Limited, Annual General Meeting, Nov 20, 2023Pro Medicus Limited, Annual General Meeting, Nov 20, 2023, at 10:00 AUS Eastern Standard Time. Location: The Yarra, 2 Wallen Road Leonda Hawthorn Australia
Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Aug 30Upcoming dividend of AU$0.17 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 September 2023. Payment date: 28 September 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.3%).
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$0.58 (vs AU$0.43 in FY 2022)Full year 2023 results: EPS: AU$0.58 (up from AU$0.43 in FY 2022). Revenue: AU$127.3m (up 35% from FY 2022). Net income: AU$60.6m (up 37% from FY 2022). Profit margin: 48% (in line with FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 22Pro Medicus Limited to Report Fiscal Year 2023 Final Results on Aug 15, 2023Pro Medicus Limited announced that they will report fiscal year 2023 final results on Aug 15, 2023
Recent Insider Transactions • Mar 15Chairman recently sold €1.9m worth of stockOn the 13th of March, Peter Kempen sold around 50k shares on-market at roughly €38.19 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
Upcoming Dividend • Feb 23Upcoming dividend of AU$0.13 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 March 2023. Payment date: 24 March 2023. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.3%).
Reported Earnings • Feb 16First half 2023 earnings released: EPS: AU$0.26 (vs AU$0.20 in 1H 2022)First half 2023 results: EPS: AU$0.26 (up from AU$0.20 in 1H 2022). Revenue: AU$56.9m (up 28% from 1H 2022). Net income: AU$27.2m (up 32% from 1H 2022). Profit margin: 48% (up from 47% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 15Pro Medicus Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 24, 2023Pro Medicus Limited announced dividend for the six months ended December 31, 2022 of AUD 0.13000000 per share. Ex-date is March 2, 2023. Record date is March 3, 2023. Payment date is March 24, 2023.
お知らせ • Jan 24Pro Medicus Limited to Report First Half, 2023 Results on Feb 15, 2023Pro Medicus Limited announced that they will report first half, 2023 results on Feb 15, 2023
Upcoming Dividend • Sep 01Upcoming dividend of AU$0.12 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.4%).
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.43 (vs AU$0.30 in FY 2021)Full year 2022 results: EPS: AU$0.43 (up from AU$0.30 in FY 2021). Revenue: AU$94.1m (up 38% from FY 2021). Net income: AU$44.4m (up 44% from FY 2021). Profit margin: 47% (up from 45% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 24%, compared to a 16% growth forecast for the Healthcare Services industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.
Upcoming Dividend • Feb 24Upcoming dividend of AU$0.10 per shareEligible shareholders must have bought the stock before 03 March 2022. Payment date: 25 March 2022. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (1.2%).
Reported Earnings • Feb 17First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$0.20 (up from AU$0.13 in 1H 2021). Revenue: AU$44.3m (up 40% from 1H 2021). Net income: AU$20.7m (up 53% from 1H 2021). Profit margin: 47% (up from 43% in 1H 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 28%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 02Upcoming dividend of AU$0.08 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 01 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.9%).
Reported Earnings • Aug 18Full year 2021 earnings released: EPS AU$0.30 (vs AU$0.22 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$68.1m (up 20% from FY 2020). Net income: AU$30.9m (up 34% from FY 2020). Profit margin: 45% (up from 41% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Mar 03New 90-day high: €30.54The company is up 69% from its price of €18.12 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.97 per share.
Upcoming Dividend • Feb 25Upcoming Dividend of AU$0.07 Per ShareWill be paid on the 19th of March to those who are registered shareholders by the 4th of March. The trailing yield of 0.3% is below the top quartile of German dividend payers (3.4%), and is lower than industry peers (1.0%).
Recent Insider Transactions • Feb 23Co-Founder recently sold €30m worth of stockOn the 18th of February, Anthony Hall sold around 1m shares on-market at roughly €29.50 per share. This was the largest sale by an insider in the last 3 months. Anthony has been a seller over the last 12 months, reducing personal holdings by €29m.
Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 37%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.
Reported Earnings • Feb 18First half 2021 earnings released: EPS AU$0.13 (vs AU$0.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$31.6m (up 7.8% from 1H 2020). Net income: AU$13.5m (up 12% from 1H 2020). Profit margin: 43% (up from 41% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 08New 90-day high: €27.85The company is up 40% from its price of €19.94 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.53 per share.
Is New 90 Day High Low • Jan 14New 90-day high: €23.11The company is up 29% from its price of €17.91 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.71 per share.
Is New 90 Day High Low • Dec 19New 90-day high: €20.91The company is up 37% from its price of €15.25 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.36 per share.
Is New 90 Day High Low • Nov 05New 90-day high: €20.58The company is up 45% from its price of €14.15 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.26 per share.
Is New 90 Day High Low • Oct 08New 90-day high: €17.07The company is up 11% from its price of €15.40 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.05 per share.